A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : NET / neoadjuvant endocrine therapy

[Related PubMed/MEDLINE]
Total Number of Papers: 21
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   NET  (>> Co-occurring Abbreviation)
Long Form:   neoadjuvant endocrine therapy
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2018 Breast MRI phenotype and background parenchymal enhancement may predict tumor response to neoadjuvant endocrine therapy. BPE
2018 Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer. PEPI
2018 Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. DDFS, DFS, OS, PD, PEPI, PR
2018 Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609). HR, TILs
2018 Neoadjuvant Endocrine Therapy: Who Benefits Most? ---
2018 Using a Neoadjuvant Approach for Evaluating Novel Therapies for Patients With Breast Cancer. HR, pCR, PEPI
2017 A Randomized Feasibility Study of 18F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor-Rich Postmenopausal Breast Cancer. 18F-FES, ER, NC
2017 Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping. NBRST, NCT, pCR
2017 Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER+ breast cancer. PEPI
10  2017 Locoregional and Overall Recurrence After Neaodjuvant Endocrine Therapy Versus Chemotherapy in Postmenopausal Women With Estrogen Receptor+ HER2- Breast Cancer. CI, HR, LRR, NCT
11  2017 Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial. ER, FEC, HER2, NAC
12  2017 Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study. BCS, CI, HR, NCDB, OR
13  2016 Multidisciplinary Approach to Neoadjuvant Endocrine Therapy in Breast Cancer: A Comprehensive Review. NCT
14  2016 Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. BCS, ORs
15  2016 Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives. ---
16  2016 Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative? AI, BCS
17  2016 Network Meta-Analysis of the Effectiveness of Neoadjuvant Endocrine Therapy for Postmenopausal, HR-Positive Breast Cancer. COR, OR, OR
18  2016 Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609). BCS, CI, HER2, HR, RFS
19  2014 Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer. AIs, BCS, DFS, HER2, HR
20  2013 Value of pre-treatment biomarkers in prediction of response to neoadjuvant endocrine therapy for hormone receptor-positive postmenopausal breast cancer. AUC, ER, HER2, HR, PgR, ROC
21  2002 Changes in extent and zonal distribution of prostatic adenocarcinoma in patients preoperatively treated with neoadjuvant endocrine therapy: analysis on whole-mounted prostatectomy specimens. PCa